Teva Pharmaceutical Industries stated it will stop producing its widely utilized painkiller Acamol in Israel and shift manufacturing to its facility in Ulm, Germany, in a cost-cutting shift that will not result in layoffs.
The company stated the decision to relocate production from its plant in Kfar Saba—employing around 1,000 workers—is part of a broader global strategy to streamline operations and align Israeli products with European standards. Versions of the drug, such as Acamol Focus, Acamol Cold in gel capsules and Acamol Forte, will continue to be produced in Israel.
Acamol, based on paracetamol, is a flagship over-the-counter drug for Teva in Israel. While the formula and per-capsule price will remain unmodifyd, Teva plans to update package sizes. The shelf version sold in pharmacies will shrink from 14 to 10 capsules, while the pharmacy-counter version will expand from 21 to 30 capsules.
Teva recently reported second-quarter earnings for 2025, posting a net profit of $282 million, reversing a loss from the same period last year. Revenue rose 1% to $8.1 billion, marking the company’s 10th straight quarter of growth. However, investors reacted negatively—shares fell 8% on Wall Street and over 4% in early Tel Aviv trading.
Leave a Reply